title: Circulating tumor cells: clinical validity and utility.
abstract: Circulating tumor cells (CTCs) are rare tumor cells and have been investigated as diagnostic, prognostic and predictive biomarkers in many types of cancer. Although CTCs are not currently used in clinical practice, CTC studies have accumulated a high level of clinical validity, especially in breast, lung, prostate and colorectal cancers. In this review, we present an overview of the current clinical validity of CTCs in metastatic and non-metastatic disease, and the main concepts and studies investigating the clinical utility of CTCs. In particular, this review will focus on breast, lung, colorectal and prostate cancer. Three major topics concerning the clinical utility of CTC are discussed-(1) treatment based on CTCs used as liquid biopsy, (2) treatment based on CTC count or CTC variations, and (3) treatment based on CTC biomarker expression. A summary of published or ongoing phase II and III trials is also presented.
authors.affiliation: Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France. luc.cabel@curie.fr.|Circulating Tumor Biomarkers Laboratory, SiRIC, Institut Curie, PSL Research University, Paris, France. luc.cabel@curie.fr.
authors.forename: Luc
authors.initials: L
authors.lastname: Cabel
authors.affiliation: Circulating Tumor Biomarkers Laboratory, SiRIC, Institut Curie, PSL Research University, Paris, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Proudhon
authors.affiliation: Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France.
authors.forename: Hugo
authors.initials: H
authors.lastname: Gortais
authors.affiliation: Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France.|Translational Immunotherapy Team, SiRIC, Institut Curie, PSL Research University, Paris, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Loirat
authors.affiliation: Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Coussy
authors.affiliation: Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France.|Circulating Tumor Biomarkers Laboratory, SiRIC, Institut Curie, PSL Research University, Paris, France.|Paris Descartes University, Paris, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Pierga
authors.affiliation: Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France.|Circulating Tumor Biomarkers Laboratory, SiRIC, Institut Curie, PSL Research University, Paris, France.|Versailles-Saint-Quentin University, Paris-Saclay, Saint Cloud, France.
authors.forename: François-Clément
authors.initials: FC
authors.lastname: Bidard
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D001706:Biopsy; D001943:Breast Neoplasms / Q000473:pathology; D015179:Colorectal Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D009369:Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009360:Neoplastic Cells, Circulating / Q000378:metabolism / Q000473:pathology*; D010338:Pathology, Clinical / Q000379:methods; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor
keywords: Biomarkers; Circulating tumor cells; Clinical trials; Clinical utility; Clinical validity